longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Tango Therapeutics

TNGX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Zai Lab -2.8%, most brokers rate it buy

    Weekly Review·7 hours ago
    - Zai Lab shares fell 2.8% to close at 24.98 USD this week, underperforming the S&P 500 index by 4.01 percentage points amid shrinking trading volume and no major catalysts. - Among 12 covering institutions, 9 rated the stock as a buy and 2 as overweight, resulting in a strong buy consensus with an average target price of 33.14 USD. - Next week's focus will center on US macroeconomic data impacting the biotechnology sector's risk appetite, while Zai Lab has no major events or earnings reports scheduled.
    ZLAB-1.19%
  • Weekly Recap | Sarepta Therap -7.16%, consensus target above spot

    Weekly Review·7 hours ago
    SRPT+1.52%SRPU0.00%
  • Weekly Recap | Novavax +5.14%, consensus target above spot

    Weekly Review·7 hours ago
    NVAX+0.28%
  • Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy

    Weekly Review·7 hours ago
    LEGN+0.26%
  • Weekly Recap | IOVA.US +7.32%, most brokers rate it buy

    Weekly Review·8 hours ago
    IOVA+1.85%
  • Weekly Recap | GENB.US -11.61%, consensus target above spot

    Weekly Review·8 hours ago
    GENB-5.25%
  • Weekly Recap | Cypherpunk Tech +14.44%, a sharp V-shaped recovery

    Weekly Review·8 hours ago
    CYPH+0.98%
  • Weekly Recap | CRISPR Therap -4.12%, most brokers rate it buy

    Weekly Review·8 hours ago
    CRSP-2.64%
  • Weekly Recap | Biogen +5.61%, closing in on record highs

    Weekly Review·8 hours ago
    BIIB+0.55%
  • Weekly Recap | BioNTech SE +2.56%, most brokers rate it buy

    Weekly Review·8 hours ago
    BNTX-0.75%
  • Weekly Recap | Abbvie +0.14%, FDA approves Parkinson's drug

    Weekly Review·8 hours ago
    ABBV-0.29%
  • Weekly Recap | IBB.US +2.55%, large-cap data flow lifts sector

    Weekly Review·10 hours ago
    IBB+0.25%